Your session is about to expire
← Back to Search
Chemotherapy
TACE + SBRT for Liver Cancer
N/A
Waitlist Available
Led By Tarita Thomas, MD, PhD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age > 18 years old
Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days
Awards & highlights
Study Summary
This trial will study whether combining two cancer treatments, SBRT and TACE, is effective for patients with HCC awaiting liver transplantation.
Who is the study for?
This trial is for adults over 18 with hepatocellular carcinoma who are on or recommended for a liver transplant list. They should be able to undergo TACE, have Childs' Class A or B7 liver function, and an ECOG performance status of 0 or 1. Pregnant women, those in other treatment studies, with certain medical conditions like active GI ulcers or bleeds, prior upper abdomen radiotherapy or liver treatments are excluded.Check my eligibility
What is being tested?
The study is testing if combining two treatments—TACE and SBRT—is effective as a temporary solution (bridging therapy) for patients with liver cancer waiting for a transplant. It's the first study of its kind and aims to enroll 40 patients into each treatment group.See study design
What are the potential side effects?
Possible side effects from TACE may include abdominal pain, fever, nausea; while SBRT could cause fatigue, skin reactions at the treatment site, and gastrointestinal symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am older than 18 years.
Select...
I am eligible for a specific liver cancer treatment as per my radiologist.
Select...
I am able to understand and agree to the study's procedures and risks.
Select...
I have liver cancer and am on or recommended for the liver transplant list.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression Free Survival
Trial Design
2Treatment groups
Experimental Treatment
Group I: B - Tace combined with SBRTExperimental Treatment2 Interventions
B- TACE combined with SBRT (experimental group).
Group II: A -Tace aloneExperimental Treatment1 Intervention
A - TACE alone (control group, current practice and treatment)
Find a Location
Who is running the clinical trial?
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,101 Total Patients Enrolled
1 Trials studying Liver Cancer
18 Patients Enrolled for Liver Cancer
Abramson Cancer Center at Penn MedicineLead Sponsor
383 Previous Clinical Trials
144,857 Total Patients Enrolled
1 Trials studying Liver Cancer
18 Patients Enrolled for Liver Cancer
Loyola UniversityOTHER
156 Previous Clinical Trials
31,382 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am older than 18 years.I am eligible for a specific liver cancer treatment as per my radiologist.I have had TACE, RFA, or a liver transplant for my liver lesion.I cannot have MRI or CT scans with contrast due to health reasons.Blood flow in the vein to part of my liver with the cancer is completely blocked.I am able to understand and agree to the study's procedures and risks.I cannot undergo radiotherapy or TACE due to health reasons.My ascites hasn't improved with medication.I am currently pregnant.I have liver cancer and am on or recommended for the liver transplant list.I am fully active or restricted in physically strenuous activity but can do light work.I have not had a GI bleed in the last 2 weeks.I have had radiation therapy to my upper abdomen or liver.I have not had an active stomach or intestinal ulcer in the last 4 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: A -Tace alone
- Group 2: B - Tace combined with SBRT
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still slots available for participants in this investigation?
"This study, which was posted on July 1st 2013 and officially updated December 3rd 2021 is no longer open to applicants. Nonetheless, there are many other clinical trials that remain actively recruiting patients at this time with a total of 2609 studies available for participation."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger